头头电子竞技

Be the most trusted biotech company

2023-09-22

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
2023-09-21

Henlius to Release the Preclinical Profiles of 2 ADC Programs at ESMO Congress 2023
2023-09-12

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
2023-09-11

The Phase 3 Clinical Study Results of a Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at WCLC 2023
2023-08-28

Henlius and HanchorBio Enter into Strategic Collaboration to Spur Innovative Immunotherapies Development
2023-08-25

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth
2023-08-17

Henlius Announces Upcoming Oral Presentation at WCLC 2023 Featuring Results for HANSIZHUANG from a Phase 3 MRCT in sqNSCLC
2023-07-27

HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
2023-07-26

Henlius completed the phase 1/2 clinical trial of HLX04-O for the treatment of Ophthalmic Diseases